Cavalry Fund I SPV I

Cavalry Fund I SPV I is a special purpose investment vehicle managed by Cavalry Fund I, a healthcare-focused investment firm based in New Jersey. The entity primarily acts as a strategic lender and investor in the life sciences and healthcare sectors, providing capital through senior secured notes and equity-linked instruments. In March 2026, the SPV acquired Ignite Proteomics LLC, a precision oncology company specializing in functional proteomics, from IMAC Holdings in a debt-for-equity transaction. Following this acquisition, the SPV facilitated the transfer of Ignite's assets to Aditxt, Inc. (Nasdaq: ADTX) to advance the commercialization of its Reverse Phase Protein Array (RPPA) platform for cancer therapy selection.